Human T-lymphotropic virus seroconversion associated with pooled human intravenous immunoglobulin therapy.
M
M
Hunter
M C
MC
Kiernan
J
J
Post
D000328:Adult; D018450:Disease Progression; D020233:Gait Disorders, Neurologic / Q000628:therapy; D015481:HTLV-I Antibodies / Q000097:blood; D015482:HTLV-II Antibodies / Q000097:blood; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D015367:Human T-lymphotropic virus 2 / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D007124:Immunoenzyme Techniques; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D016472:Motor Neuron Disease / Q000628:therapy*
D015481:HTLV-I Antibodies; D015482:HTLV-II Antibodies; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors